LeishGen: Advanced Genomic Platforms for Drug Resistance Biomarkers in Leishmania infantum

LeishGenApp offers a deep dive into the Leishmania infantum genome, leveraging whole-genome sequencing and a specialized panel of 15 biomarkers as key indicators of drug resistance.

• Genomic insights for precision care: in just two weeks, LeishGenApp delivers a comprehensive report on drug resistance, supporting researchers and clinicians in developing effective treatment plans.
• Broad applicability: designed for both research and clinical settings, LeishGenApp is ideal for analyzing Leishmania infantum samples from humans and animals with cultured parasite isolates (10⁷ p/ml), aligning with the One Health approach.

LeishGenR simplifies the diagnostic process by detecting drug-resistance biomarkers to allopurinol, antimonials and miltefosine directly from clinical samples, eliminating the need for culturing.

• Direct-from-sample accuracy: LeishGenR provides reliable detection of drug-resistance markers directly from clinical samples with lower parasite loads.
• User-Focused for Clinicians: LeishGenR is designed with clinicians in mind, with a streamlined process and rapid feedback to support timely therapeutic decisions, enhancing patient outcomes and helping mitigate resistance spread in endemic regions.

LeishGenApp and LeishGenR align with Nano1Health’s commitment to the One Health initiative, providing powerful tools for managing zoonotic diseases through cutting-edge genomic insights. Together, they support sustainable healthcare strategies by addressing the challenges of drug resistance at the intersection of human and animal health.